Barry M G, Macmathuna P, Younger K, Keeling P W, Feely J
Department of Pharmacology and Therapeutics, Trinity College, Dublin.
Br J Clin Pharmacol. 1991 Apr;31(4):488-91. doi: 10.1111/j.1365-2125.1991.tb05568.x.
The pharmacokinetics of antipyrine were studied in seven zinc deficient patients with hepatic cirrhosis, before and after zinc supplementation. Each patient received zinc sulphate 660 mg daily for 30 days, restoring zinc status to normal as assessed by leucocyte zinc concentration. Antipyrine clearance was significantly reduced (P less than 0.05) and antipyrine elimination half-life increased (P less than 0.05) following administration of zinc sulphate without significant alteration in the apparent volume of distribution. It is concluded that supplementation of the zinc deficiency associated with hepatic cirrhosis impaired the hepatic oxidative metabolism of antipyrine.
对7例肝硬化伴锌缺乏患者在补锌前后进行了安替比林的药代动力学研究。每位患者每日口服硫酸锌660毫克，持续30天，根据白细胞锌浓度评估，锌水平恢复正常。服用硫酸锌后，安替比林清除率显著降低（P<0.05），安替比林消除半衰期延长（P<0.05），而表观分布容积无显著变化。研究得出结论，补充与肝硬化相关的锌缺乏会损害肝脏对安替比林的氧化代谢。
